The global cancer tissue diagnostic market is poised for remarkable growth, with projections indicating an increase from USD 15,302.2 million in 2024 to USD 23,516.2 million by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of 4.5% over the forecast period, highlighting the urgent need for advanced diagnostic solutions amid the rising incidence of cancer worldwide.
The surge in cancer cases globally is a primary driver of this growth, intensifying the demand for effective cancer diagnostic tools. With advancements in diagnostic technologies and methodologies, healthcare providers can enhance diagnostic accuracy and enable earlier detection of cancer, significantly impacting patient outcomes.
The increasing prevalence of cancer is further fueling demand for cancer tissue diagnostics kits, particularly as clinical facilities are focused on processing larger volumes of plasma and generating high concentrations of eluates. These developments not only support patient care but also provide a solid foundation for market expansion.
Leading companies within the cancer tissue diagnostics sector are prioritizing research and development, investing in innovative product development to broaden their portfolios and strengthen their global presence. This focus on innovation is vital as the medical community continues to combat the challenges posed by cancer, including high false-positive rates and treatment uncertainty.
Despite significant advancements in detection and treatment, cancer remains the deadliest global illness. Medical professionals and researchers are actively exploring advanced technologies, including artificial intelligence, to enhance cancer detection and treatment approaches.
As the cancer tissue diagnostic market evolves, stakeholders must remain committed to leveraging technology and innovation to address the pressing challenges of cancer diagnostics, ultimately improving patient care and outcomes.
Key Takeaways from the Market Study:
- By product type, molecular diagnostic test kits held the highest share of 42.7% in 2023 in the market.
- In 2023, by cancer type, the breast cancer segment held a substantial share of 22.7%.
- The United States is expected to surge at a CAGR of 3.1% by 2034.
- China is projected to rise at 6.8% CAGR by 2034.
- Based on cancer type, the breast cancer segment is expected to rise at 5.1% CAGR by 2034.
“Private diagnostic centers worldwide are expanding due to rising demand for imaging and increasing workload on public hospitals. They are also working on liquid biopsy and animal cancer therapies, offering profitable growth prospects for global cancer diagnostic market,”- says Future Market Insights (FMI) lead analyst.
Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!
Competitive Landscape:
Expansion of product portfolios by launching technologically advanced products is a key strategy of the leading companies and manufacturers. Key companies focus on collaborations to compete with competitors in the market.
For instance,
- In March 2022, Thermo Fisher Scientific launched the CE-IVD-marked next-generation sequencing instrument for clinical labs.
- In March 2021, F. Hoffmann-La Roche Ltd. merged with GenMark Diagnostics, Inc., to access a novel technology for testing a wide range of pathogens with one patient sample.
Key Companies Profiled:
- Abbott Laboratories
- F.Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Merck KGaA (Sigma-Aldrich Co., LLC)
- Danaher Corporation (Cepheid)
- Agilent Technologies, Inc.
- Quest Diagnostics Incorporated
- Bio Rad Laboratories Inc.
- QIAGEN
- Illumina, Inc.
- Enzo Life Sciences, Inc.
- BioGenex
- Bio SB
- Nanoprobes, Inc.
- Creative Biolabs.
- Takara Bio Inc.
Cancer Tissue Diagnostics Industry Segmentation by Category:
By Product:
- In Situ Hybridization (ISH) Test Kits
- Fluorescent In Situ Hybridization (FISH) Kits
- Chromogenic In Situ Hybridization (CISH) Kits
- Molecular Diagnostics Test Kits
- Polymerase Chain Reaction (PCR) Kits
- Next-generation Sequencing (NGS) Kits
- Companion Diagnostics Test Kits
- Genetic Testing Kits
- Biomarker Testing Kits
- Immunohistochemistry (IHC) Test Kits
By Cancer:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Ovarian Cancer
- Hematologic Cancer
- Liver Cancer
- Pancreatic Cancer
- Skin Cancer (Melanoma)
- Others
By End-user:
- Hospitals
- Specialty Centers
- Long-term Care Centers
- Diagnostic Centers
- Academic & Research Institutes
By Region:
- North America
- Latin America
- East Asia
- South Asia & Pacific
- Western Europe
- Eastern Europe
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
